Revvity stock

RVTY · NYSE · USD

Compare Revvity
$145.22Change from previous close: −4.20%Absolute change: −$6.37

Close · November 20, 2026

Price history

+54.46% over the period

1 year: from $94.02 (November 20, 2025) to $145.22 (November 20, 2026), +54.46%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$145.22
October 30, 2026$157.00
September 30, 2026$152.89
August 31, 2026$128.67
July 31, 2026$112.52
June 30, 2026$111.26
May 29, 2026$104.55
April 30, 2026$86.62
March 31, 2026$87.61
February 27, 2026$98.31
January 30, 2026$108.80
December 31, 2025$96.75
November 28, 2025$104.41
November 20, 2025$94.02

At a glance

TickerLandia's take on Revvity

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$81.22
52-wk high$171.74

−15.44% from the 52-week high

Analysts · 18 analysts

Average target$171.40+18.03% vs. price

Buy 6 · Hold 11 · Sell 1 · Buy

TickerLandia Fingerprint: Revvity

Compared with similar companies: very strong momentum.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 888 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Revvity is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Revvity's P/E today is 70.2, above the median of its last 10 fiscal years (29.4; between 19.7 and 50.9 from 2016 to 2025). Revvity's P/E (trailing 12 months): 64.5, +90% against the median of a group of 9 similar companies (33.9).

P/E compared with its history

Compared with 9 similar companies

Revvity's metrics compared with similar companies
MetricRevvityPosition in the groupBand
P/E (trailing 12 months)64.5Middle
Forward P/E24.4Middle
Operating margin16.7%Middle
ROE3.5%Low
Debt/equity0.38Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Revvity. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$728.9M

Latest quarter · Q3 2026

Net income

$62.3M

Latest quarter · Q3 2026

Quarterly net margin

8.5%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$16.21B
P/E
64.5
EPS
$2.25
Volume
1.66M
Daily trading
€259.56M
Dividend yield
0.19%

How Revvity is changing

All results
  • Revenue fell 5.5% a year on average over the last 5 years

  • Operating margin fell from 22.4% to 12.5%

  • Free cash flow equal to 88% of net income

Returns

Revvity returns with dividends

$1,000 invested in Revvity 5 years ago, on November 22, 2021, would be worth $809 today with dividends reinvested: −19.13% in total, −4.16% per year. On price alone it would be $799 (−20.10%).

PeriodRevvityS&P 500$1,000 becomes
1 month−6.92%−10.40%$931
6 months+53.19%−7.03%$1,532
Year to date+50.10%+0.95%$1,501
1 year+54.83%+5.68%$1,548
3 years+66.10%+51.96%$1,661
5 years−19.13%+47.57%$809
10 years+195.22%+214.37%$2,952

Over the last 6 months it has done better than 94% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Revvity: technical analysis

Revvity shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 27.8% below its highest close since January 2, 1990 ($201.06, December 31, 2021).

Trend
No clear trend
RSI (14 sessions)
41
Between 30 and 70
vs 200-session average
+26.10%

Active signals

  • Close below the low of the previous 20 sessions.

Support and resistance

Price areas where Revvity has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$148.04+1.94%2 touches, last on November 6, 2026
  2. Last price$145.22
  3. Support$116.30−19.91%5 touches, last on August 18, 2026
  4. Support$107.88−25.72%2 touches, last on August 4, 2026
  5. Support$104.14−28.29%7 touches, last on July 21, 2026

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
1.21
Volatility (60 sessions, annualised)
43.7%
Largest fall in the last year
−30.14%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Revvity: seasonality

Average monthly price change over 37 years

+2.9%Jan+0.4%Feb−1.3%Mar−0.5%Apr+3.6%May+0.2%Jun+0.4%Jul+0.7%Aug−0.0%Sep+2.0%Oct+1.7%Nov+3.7%Dec

Over the last 37 years, the strongest month for Revvity has been December: +3.70% on average, positive in 25 years out of 36. The weakest has been March: −1.25% on average, positive in 17 years out of 37. November, the current month, has been positive in 24 years out of 36 (+1.68% on average).

Show chart data
MonthAverageMedianPositive years
January+2.86%+2.12%20 of 36
February+0.38%+2.02%22 of 37
March−1.25%−0.57%17 of 37
April−0.55%−0.54%16 of 37
May+3.61%+3.41%26 of 37
June+0.17%−1.48%16 of 37
July+0.36%+1.13%20 of 37
August+0.72%+0.81%19 of 37
September−0.05%−1.49%16 of 37
October+1.97%+2.55%23 of 37
November+1.68%+2.10%24 of 36
December+3.70%+3.05%25 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Revvity and its competitors

Known for its EUROIMMUN, IDS-iSYS and DELFIA diagnostic assays, BioLegend antibodies and Cellometer cell counters, Revvity offers instruments, reagents, software and services for health sciences. Its diagnostics range covers early detection screening, including pregnancy and early childhood tests for genetic disorders such as Down syndrome and hypothyroidism, as well as infectious disease testing. Research tools support genomic workflows, oncology, immunodiagnostics and drug discovery, with products such as Dharmacon reagents and AlphaLISA assays.

Headquarters
Waltham, United States
Employees
11,000
Founded
1937
Chief executive
Prahlad Singh
Revvity and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
RevvityRVTY$16.21B16.7%64.5+53.19%
Medpace HoldingsMEDP$17.08B21.4%33.9+44.72%
Charles River Laboratories InternationalCRL$15.06B14.3%341.7+101.45%
ICON PublicICLR$13.99B2.7%74.7+62.23%
Guardant HealthGH$19.73B-39.4%—+26.84%
Quest DiagnosticsDGX$28.42B14.9%25.7+33.31%

Same industry or related industries, similar size. Compare Revvity with its competitors · Full profile